Improvement in the management of Psoriatic Arthritis (PsA)

188 Pages·2016·13.04 MB·English

Improvement in the
management of
Psoriatic Arthritis
Summer 2016
GBL/HUD/0616/0720
Executive
summary
This study was commissioned and solely funded by AbbVie
AbbVie had no role in the conduct of the study, collection, management, analysis and Home
interpretation of data, or preparation of this report
Key
findings
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 1
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720
Executive Findings
1 5
summary Page 24
Page 4
Contents
Detailed site
Context
2 6 specifications
Page 12
Page 125
Goals Appendix
43 7
Page 18 Page 177
Approach
Home
4
Page 20
Key
findings
©© 22001166 KKPPMMGG IInntteerrnnaattiioonnaall CCooooppeerraattiivvee ((''KKPPMMGG IInntteerrnnaattiioonnaall'')),, aa SSwwiissss eennttiittyy.. MMeemmbbeerr ffiirrmmss ooff tthhee KKPPMMGG nneettwwoorrkk ooff iinnddeeppeennddeennttffiirrmmss aarree aaffffiilliiaatteedd wwiitthh KKPPMMGG
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entiIItnny.tt eeMrrennmaattbiiooernn faairllm.. KKs PPofMM thGGe KIInnPttMeerrGnn naaettiitoownnoaarkll ppofrr ooinvvdiieddpeeessn dnneoon tccflliiireemnnstt assreee rravvffiiicclieeatsse..d NN wooit hmm KeePmmMbbGee Inrr tffeiirrrnmmat ihhonaaassl .aa KnnPyyM aaGuu Ittnhhteoorrrniittayyti ottnooa ool pbbrlloiiggviaadtteees nooorr cbbliiiennnddt sKKePPrvMMiceGGs .II nnNttoee mrrnneaamttbiiooennr aafillr moorr h aaanns yya nooytt ahhueethrr ommriteeymm tobb oeebrrli gffaiirrtmme o ttrhh biiirrnddd 2
KPMG International or any other member firm third parties, nor does KPMG Inpptaaerrrnttiiaeetisso,,n nnaloo hrra vddeoo aeenssy KKsuPPcMMh aGGu tIIhnnottreeitrrynn taaott oiioobnnligaaall thhe aaovvreeb inaadnn yyan ssyuu mccehhm aabuuettrhh fooirmrriitt.yy A ttlloo r igoohbbtllsiigg reaastteeer vooerrd bb.iinndd aannyy mmeemmbbeerr ffiirrmm.. AAllll rriigghhttss rreesseerrvveedd..
GBL/HUD/0616/0720
How to navigate through the report
NFaivnidgiantgiosn
Executive Summary Context Goals
Pages 4–11 Pages 12–17 Pages 18–19
Summary of the context, goals, approach Disease background, epidemiology, clinical Details on the aims and objectives
and key findings from the report and economic burden of the project
Approach Findings Detailed site specifications
Pages 20–23 Pages 24–124 Pages 125–176
Information on how the research Compilation on the project findings, Detailed information on the visited
was conducted and who was including the patient pathway in PsA, key centres, including the overview of
involved challenges and interventions to help the teams, their key strengths and
address them challenges faced
Home
Key
findings
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 3
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720
Executive
summary
HHoommee
KKeeyy
ffiinnddiinnggss
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 4
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GGBBLL//HHUUDD//00661166//00772200
Executive summary (1/7)
Executive
summary
Psoriatic Arthritis PsA is characterised
AbbViesponsored
(PsA) is a form of by a varied clinical course
KPMGto produce an
chronic inflammatory arthritis but can lead to progressivejoint
independent reporton PsA care
associated with psoriasis, destruction, disabilityand
in collaboration with the Group
a skin condition characterised impaired qualityof life. In addition,
for Research and Assessment
by red, flaky patches on the patients with PsA are at an increased
of Psoriasis and Psoriatic
skin. PsA occurs in approximately risk of a number of comorbidities,
Arthritis (GRAPPA) with the aim
30% of patients with psoriasis including diabetes, metabolic
of improving the quality and
and develops on average 10 syndrome, depression
efficiency of care for PsA
years after the onset and cardiovascular
patients globally
of psoriasis 1 diseases 2
Independent report
AbbVie
KPMG
GRAPPA
Context
Goals
Over the last decade,
By doing so, we aimed to
the management of PsA has
identify, document and share The goal of this
been improved by the introduction
practices to help increase the project was to collate
of new treatment options.
awareness of PsA, promote information andviews on key
However, a number of
timely and accurate diagnosis, initiatives to improve care
unmet needs in PsA care remain,
increase the consistency of care from clinicians and
which place a significant clinical, Home
and, ultimately, improve patients in multiple
social and economic burden on
outcomes for patients worldwide centres
patients, their families
with PsA
and society
Key
findings
Sources: 1: Gladman, D.D. et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 64:ii14–ii17; 2: Ogdie, A., et al (2015) Recognizing and managing comorbidities
in psoriatic arthritis. Curr Opin Rheumatol. 27(2):118-26
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 5
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720
Executive summary (2/7)
Executive
summary
Click on each row of the table below to go to the relevant site specific section
GRAPPAselected
7 centres around
the world to participate
in this project. They were
picked to represent a variety
of geographies, healthcare
systems, care settings Centre Location
and different
Findings were
access to specialties Boston, US
collated into the
Whenever possible,
following report which Note: We also interviewed a dermatologist-rheumatologist from the Tufts Medical Center in Boston
nearby community centres
was then reviewed bythe
were included to understand
participating centresas well Toronto, Canada
the challenges in PsA
as members of GRAPPA
care within this Note: We also interviewed a rheumatologist from the Women’s College Hospital in Canada
to ensure the validity of
particular ecosystem
the findings
Lübeck, Germany
presented
Buenos Aires, Argentina
A group of
Approach ex–scientists and
KPMG gathered
ex–clinicians from KPMG
stakeholders’ views on
visited these centres and London, UK
five key areas: challenges in
engaged with a range of
PsA care, interventions
stakeholdersincluding
likely to address them,
rheumatologists,
networks, patient– Groote Schuur Hospital Cape Town,South Africa
dermatologists,
centricity and Cape Town
nurses, patients Home
benefit creation
and patient
organisations The Prince of Wales Hong Kong, China
Hospital, Hong Kong
Key
findings
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 6
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720
Executive summary (3/7)
Executive
summary
Key findings (1/5):
— Following the discussions with specialists and patients, the patient pathway in PsA was divided into four phases: 1. Pre–diagnosis, 2. Referral and
diagnosis, 3. Treatment initiation and management and 4. Follow–up
— Challenges:The stakeholders identified a number of challenges that persist along the patient pathway. Limited awareness of PsA among non–
rheumatologists was recognised as a challenge by all the visited centres (100%) followed by a siloed approach to care (86%), late referral and
diagnosis (71%) and an inadequate management of comorbidities (57%)
Pre–diagnosis Referral and Treatment initiation Follow–up
diagnosis and management
— Limited of — Lack of screening — Siloed approach to — Inadequate
awareness of care in secondary, management of
PsA among HCPs tertiary and comorbidities
and patients community centres
— Delayed referrals — Gaps in clinical — Lack of regular
management follow–up
Home
— Challenges with — Challenges
differential diagnosis associated with the
use of biologics
Key
findings
— Lack of patient
Click on each small circle to go to the relevant ‘challenge’ centricity
Source: KPMG interviews
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 7
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720
Executive summary (4/7)
Executive
summary
Click on each small circle to go to the relevant ‘challenge’
Key findings (2/5):
Click on flag row to go to the relevant case study
— Interventions: During the centre visits we identified 24 solutions to improve care across the different phases of the patient pathway. These are further
supported by 29 detailed case studies which provide detailed descriptions of how the visited centres have implemented them
Limited awareness of PsA
among HCPs and patients
Many clinicians are not aware of the risk
of musculoskeletal disease in patients
with psoriasis
— Education of GPs and dermatologists
1. As easy as 'PSA'
2. Peer education
— Education of patients with psoriasis
3. Patient and peer education
Pre–diagnosis
Lack of screening Delayed referral to a Challenges with differential
rheumatologist diagnosis
There is a lack of regular
screening among patients Patients are often referred to a Following a referral, diagnosis of PsA
with psoriasis rheumatologists several years can remain challenging even to
after symptom onset experienced rheumatologists
— Regular screening — Early referral — Consistent assessment criteria
Home
— Refinement and/or development of 7. Referral forms for GPs — Interdisciplinary approach
new screening tools 8. Self-referral scheme — Use of diagnostic equipment
4. PASE 9. Outreach activities 11. Radiologists–ultrasonographers
Rdefiaegrrnaol sainsd 5. ToPAS — Networks and referral pathways Kfinedyi ngs
6. PEST 10. Hospital network
Note: The flags represent the country of the centre in which the intervention was observed
Source: KPMG interviews
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 8
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720
Executive summary (5/7)
Executive
summary
Click on each small circle to go to the relevant ‘challenge’
Key findings (3/5):
Click on flag to go to the relevant case study
— Interventions: During the centre visits we identified 24 solutions to improve care across the different phases of the patient pathway. These are further
supported by 29 detailed case studies which provide detailed descriptions of how the visited centres have implemented them
Siloed approach to care in secondary, Challenges associated with the use of biologics
tertiary and community centres
Many effective treatment options are available for PsA;
Although PsA affects both joints and skin, there is however, access to these therapies can be reduced or delayed
often little coordination of care between different for some patients, especially in lower–income areas
specialties, especially in community–based clinics
— Improved coordination of dermatology and — Enrolment of patients into clinical trials
rheumatology services
20. PsA research clinic
12. –16. Combined clinics — Development of relationships with commissioners
17. Multidisciplinary care
— Development of networks and relationship between
community–based centres
18. The Arthritis Programme
19. Developing relationships between HCPs
Gaps in clinical management Lack of patient centricity
TrePartem–deinatg innoitsiaistion
and management Although many effective PsA therapies have been As patients become more engaged in healthcare, they
introduced over the last decade, many patients do want to be empowered to manage their own health.
not respond to their treatment or may lose the However, many centres could do more to be truly patient–
initial response over time centric
Home
— Use of protocols and treatment algorithms — Improved communication between HCPs and patients and
— Development and validation of new outcome engagement of patients in their care
measures in PsA 21. Pregnancy clinics
Key
— Development of educational programmes for patients findings
22. Patient centricity
— Patient education by the medical office staff
Note: The flags represent the country of the centre in which the intervention was observed
Source: KPMG interviews — Collaboration with patient associations
© 2016 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independentfirms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind 9
KPMG International or any other member firm third parties, nor does KPMG International have any such authority to obligate orbind any member firm. All rights reserved.
GBL/HUD/0616/0720